Targets › MUC5AC
1 program from 1 company in 1 trial: 1 Phase 2; Respiratory; next expected readout Dec 2027.
Gel-forming glycoprotein of gastric and respiratory tract epithelia that protects the mucosa from infection and chemical damage by binding to inhaled microorganisms and particles that are subsequently removed by the mucociliary system. Interacts with H.pylori in the gastric epithelium, Barrett's esophagus as well as in gastric metaplasia of the duodenum (GMD). (UniProt, P98088)
Open in Phaseline: the race on MUC5AC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Institute of Environmental Health Sciences (NIEHS) | hymecromone Mucin secretion inhibitor; reduces excessive mucus production in airways | MUC5AC | Phase 2 | Interstitial Lung Disease | Dec 2027 |
Interstitial Lung Disease (1)
small molecule (1)
National Institute of Environmental Health Sciences (NIEHS) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.